Literature DB >> 2383478

Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach.

Z Eshhar1, G Gross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2383478      PMCID： PMC2149517     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN： 0306-9443


× No keyword cloud information.
  9 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 2.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies.

Authors:  R K Jain
Journal:  J Natl Cancer Inst       Date:  1989-04-19       Impact factor: 13.506

3.  Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity.

Authors:  G Gross; G Gorochov; T Waks; Z Eshhar
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

Review 4.  Cellular immunity against tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Cancer Res       Date:  1969       Impact factor: 6.242

Review 5.  Targeting of cytotoxic cells with heterocrosslinked antibodies.

Authors:  D M Segal; J R Wunderlich
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

6.  Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells.

Authors:  A Ochi; R G Hawley; T Hawley; M J Shulman; A Traunecker; G Köhler; N Hozumi
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728
  9 in total
  5 in total

Review 1.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 2.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  Improving immune-vascular crosstalk for cancer immunotherapy.

Authors:  Yuhui Huang; Betty Y S Kim; Charles K Chan; Stephen M Hahn; Irving L Weissman; Wen Jiang
Journal:  Nat Rev Immunol       Date:  2018-01-15       Impact factor: 53.106

Review 4.  Receptor-Targeted Glial Brain Tumor Therapies.

Authors:  Puja Sharma; Waldemar Debinski
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

Review 5.  Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.

Authors:  Zhidong Wang; Yu J Cao
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.